References
- Belliard AM, Lacour B, Farinotti R, Leroy C. (2004). Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells. J Pharm Sci 93:1524–36.
- Chanteux H, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. (2005). Accumulation and oriented transport of ampicillin in Caco-2 cells from its pivaloyloxymethylester prodrug, pivampicillin. Antimicrob Agents Chemother 49:1279–88.
- Englund G, Jacobson A, Rorsman F, et al. (2007). Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm Bowel Dis 13:291–7.
- Fujisawa K, Nasu K, Arima K, et al. (2000). Production of interleukin (IL)-6 and IL-8 by a choriocarcinoma cell line, BeWo. Placenta 21:354–60.
- Furuta R, Ando T, Watanabe O, et al. (2007). Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis. J Gastroenterol Hepatol 22:261–7.
- Gopu B, Dileep R, Rani MU, et al. (2015). Protective role of curcumin and flunixin against acetic acid-induced inflammatory bowel disease via modulating inflammatory mediators and cytokine profile in rats. J Environ Pathol Toxicol Oncol 34:309–20.
- Gupta A, Dai Y, Vethanayagam RR, et al. (2006). Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374–83.
- Haslam IS, Wright JA, O'reilly DA, et al. (2011). Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2). Drug Metab Dispos 39:2321–18.
- Le Vee M, Lecureur V, Stieger B, Fardel O. (2009). Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos 37:685–93.
- Li GF, Wang CX, Yan Y, et al. (2008). Permeabilities of rebamipide via different intestinal mucosa in the diffusion chamber in vitro. Yao Xue Xue Bao 43:314–17.
- Makiyama K, Takeshima F, Hamamoto T. (2005). Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci 50:2323–9.
- Michot JM, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. (2004). Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. Antimicrob Agents Chemother 48:2673–82.
- Nishida A, Hidaka K, Kanda T, et al. (2016). Increased expression of interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory bowel disease. Inflamm Bowel Dis 22:303–14.
- Shintani S, Toba Y, Umezato M, et al. (1989). General pharmacology of the anti-ulcer agent, (±)-2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid (OPC-12759). Iyakuhin Kenkyu 20:499–521.
- Taipalensuu J, Törnblom H, Lindberg G, et al. (2001). Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164–70.
- Tavelin S, Gråsjö J, Taipalensuu J, et al. (2002). Applications of epithelial cell culture in studies of drug transport. Methods Mol Biol 188:233–72.
- Tazuke Y, Drongowski RA, Teitelbaum DH, Coran AG. (2003). Interleukin-6 changes tight junction permeability and intracellular phospholipid content in a human enterocyte cell culture model. Pediatr Surg Int 19:321–5.
- Töllner K, Brandt C, Römermann K, Löscher W. (2015). The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide. Eur J Pharmacol 746:167–73.
- Uchida Y, Kamiie J, Ohtsuki S, Terasaki T. (2007). Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res 24:2281–96.
- Yamasaki K, Kanbe T, Chijiwa T, et al. (1987). Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol 142:23–9.
- Yamasaki K, Ishiyama H, Imaizumi T, et al. (1988). Anti-ulcer activity of OPC-12759 against experimental gastric ulcer models. Jpn Pharm Ther 16:1997–2005.
- Yamasaki K, Ishiyama H, Imaizumi T, et al. (1989). Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Jpn J Pharmacol 49:441–8.
- Zhou Z, Dai C, Liu WX. (2015). Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis. Hepatogastroenterology 62:829–37.